AXNX News and Press, Axonics Modulation Technologies Inc. From 04/24/23

2023-04-24 06:22:01 ET Axonics ( NASDAQ: AXNX ) said it acquired a lead placement solution from Radian which complements the company's existing sacral neuromodulation (SNM) offering. The company acquired the assets of Radian from Intermed Labs for undisclosed terms. SNM is a...

Axonics, Inc. (Nasdaq: AXNX), a global medical technology company that is developing and commercializing novel products for the treatment of bladder and bowel dysfunction, today announced the acquisition of a lead placement solution from Radian, LLC that complements Axonics’ existing sacra...

Axonics, Inc. (Nasdaq: AXNX), a global medical technology company that is developing and commercializing novel products for the treatment of bladder and bowel dysfunction, is scheduled to report first quarter 2023 financial results after the close of trading on Monday, May 1. Axonics will hos...

Axonics, Inc. (Nasdaq: AXNX), a global medical technology company that is developing and commercializing novel products for the treatment of bladder and bowel dysfunction, today announced it ranked No. 2 on the Financial Times 2023 list of the fastest growing companies in the Americas. This f...

2023-03-24 09:17:11 ET Shares of MedTech firm Axonics ( NASDAQ: AXNX ) rose pre-market Friday after Needham upgraded it to Buy from Hold with a $71 per share target, arguing that the company's 2023 revenue guidance looked "conservative.' Axonics ( AXNX ), a developer of ...

Axonics, Inc. (Nasdaq: AXNX), a global medical technology company that is developing and commercializing novel products for the treatment of bladder and bowel dysfunction, is participating as a platinum sponsor of the Society of Urodynamics, Female Pelvic Medicine & Urogenital Reconstruction ...

Axonics, Inc. (AXNX) Q4 2022 Earnings Conference Call March 01, 2023, 04:30 PM ET Company Participants Neil Bhalodkar - VP of IR Raymond Cohen - CEO Dan Dearen - President and CFO Conference Call Participants Travis Steed - Bank of America Larry Biegels...

Axonics press release ( NASDAQ: AXNX ): Q4 GAAP EPS of $0.01 beats by $0.25 . Revenue of $85.9M (+61.8% Y/Y) beats by $1.76M . Reiterated fiscal year 2023 revenue guidance of $342 million. The consensus FY 2023 revenue estimate is $342.27M. For further d...

Generated record quarterly revenue of $86 million, an increase of 62% y/y Reported fiscal year 2022 revenue of $274 million, an increase of 52% y/y Reiterated fiscal year 2023 revenue guidance of $342 million, an increase of 25% y/y Axonics, Inc. (Nasdaq: AXNX), a global...

Summary Axonics presents with robust fundamentals and unit economics around its sacral neuromodulation segment. The company confirmed FY22 numbers above consensus, guides to FY23E revenues above the Street as well. Shares attractive given top-line growth rates, current sales multipl...